39,800 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Purchased by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 39,800 shares of the biotechnology company’s stock, valued at approximately $299,000.

Several other large investors have also bought and sold shares of BCRX. Xponance Inc. lifted its position in BioCryst Pharmaceuticals by 9.1% during the 4th quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 1,242 shares during the period. Sei Investments Co. grew its holdings in BioCryst Pharmaceuticals by 2.8% in the fourth quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company’s stock worth $430,000 after purchasing an additional 1,537 shares during the period. Captrust Financial Advisors increased its stake in shares of BioCryst Pharmaceuticals by 19.4% during the third quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 2,644 shares in the last quarter. SkyView Investment Advisors LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Arizona State Retirement System boosted its position in shares of BioCryst Pharmaceuticals by 6.6% in the 4th quarter. Arizona State Retirement System now owns 57,001 shares of the biotechnology company’s stock worth $429,000 after purchasing an additional 3,518 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on BCRX shares. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. JMP Securities restated a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Needham & Company LLC upped their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Evercore ISI raised their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $11.00 target price (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $15.57.

BioCryst Pharmaceuticals Stock Performance

BCRX opened at $6.83 on Monday. The company’s 50-day simple moving average is $8.14 and its two-hundred day simple moving average is $7.80. The stock has a market capitalization of $1.43 billion, a P/E ratio of -11.20 and a beta of 1.84. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same quarter last year, the business posted $0.28 EPS. The firm’s revenue for the quarter was up 40.8% compared to the same quarter last year. Research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.